TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11053698

Group type: EXPERIMENTAL
Intervention: Patients with acute coronary syndrome (ACS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control patients (neither ACS nor CHF)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure (CHF)
Number of subjects: 57
Study: 8894888

Group type: EXPERIMENTAL
Intervention: Health visitor follow-up intervention; patients seen at home shortly after discharge and screened for new dependency and support needs.
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group with no special arrangements made.
Number of subjects: 414
Study: 2004365

Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 12 g/m2/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 24 g/m2/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 30 g/m2/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically or parenterally
Number of subjects: 14
Study: 6838743

Group type: EXPERIMENTAL
Intervention: Sitting position after extradural injection
Number of subjects: 89

Group type: COMPARATOR
Intervention: Left lateral position throughout
Number of subjects: 89
Study: 31217316

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: VR plus betahistine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 183
Study: 27514499

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate (GFR)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Aortic regurgitation grade postprocedure ≥ 2
Number of subjects: 221
Study: 26297943

Group type: EXPERIMENTAL
Intervention: Solomon technique
Number of subjects: 287

Group type: COMPARATOR
Intervention: Standard laser surgery technique
Number of subjects: 287
Study: 25483468

Group type: EXPERIMENTAL
Intervention: History of influenza immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to influenza during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single message exposure
Number of subjects: 0
Study: 22914552

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% of energy derived from fat)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy derived from fat)
Number of subjects: 734
Study: 19082870

Group type: EXPERIMENTAL
Intervention: Protocol A (retrospective ECG-gating at 120 kV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protocol B (retrospective ECG-gating at 100 kV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protocol C (prospective ECG-triggering at 120 kV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protocol D (prospective ECG-triggering at 100 kV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protocol E (prospective ECG-triggering at 100 kV with attenuation-based tube current modulation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of 100 kV protocols to 120 kV protocols
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of prospective versus retrospective ECG-gating
Number of subjects: 100

Group type: COMPARATOR
Intervention: Protocol D vs Protocol E
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of CTDI(vol) and heart rate for protocol A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of CTDI(vol) and heart rate for protocol B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mean image noise across all protocols
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of image noise with body weight
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of image noise with BMI
Number of subjects: 100
Study: 17242321

Group type: EXPERIMENTAL
Intervention: Daily SSRI use
Number of subjects: 5008
Study: 15655141

Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo twice weekly
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo once weekly
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prophylactic ciclopirox once weekly
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prophylactic ciclopirox once every 2 weeks
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Vehicle (control) for prophylaxis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo (both treatment and prophylaxis)
Number of subjects: 1000
Study: 12106522

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 9527938

Group type: EXPERIMENTAL
Intervention: sucrose‐dipped pacifier
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EMLA analgesic cream
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sucrose and EMLA combination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sucrose alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: control (water‐dipped pacifier only)
Number of subjects: 80
Study: 7874096

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg three times daily
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 2231096

Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 1000 mg/day for 3 days (group 1)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 500 mg/day for 3 days (group 2)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 250 mg/day for 3 days (group 3)
Number of subjects: 663
Study: 412015

Group type: EXPERIMENTAL
Intervention: Computer aided monitoring system
Number of subjects: 810
Study: 31319789

Group type: EXPERIMENTAL
Intervention: Readiness Assessment for Pragmatic Trials (RAPT) model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RAPT scoring guidelines
Number of subjects: 30
Study: 28185976

Group type: EXPERIMENTAL
Intervention: 10 mg oral glibenclamide daily for 10 days, n = 29
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo in the same dosage, n = 23
Number of subjects: 66
Study: 25956661

Group type: EXPERIMENTAL
Intervention: Tavaborole topical solution, 5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 22998386

Group type: EXPERIMENTAL
Intervention: Essential oil mouth rinse (Listerine(®) Coolmint; Johnson & Johnson) used twice per day as an adjunct to mechanical plaque control.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouth rinse used twice per day as an adjunct to mechanical plaque control.
Number of subjects: 50
Study: 21080030

Group type: EXPERIMENTAL
Intervention: Presentation of triads with one, two, or all three categories represented on each trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context items' category membership explicitly identified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variations in learners' prior knowledge of the relationship between the target and context items.
Number of subjects: 0
Study: 20635735

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy (AT)
Number of subjects: 3871
Study: 17266173

Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation (1200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15335114

Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Constant-flow nebulizer (CFN)
Number of subjects: 72
Study: 11174476

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (Menorest) at dosages of 25, 50, 75, or 100 microg/d for 3 years
Number of subjects: 325

Group type: COMPARATOR
Intervention: Switch to 17beta-estradiol (Menorest) at dosages of 25, 50, 75, or 100 microg/d after 2 years of placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: All dosage groups of 17beta-estradiol (Menorest)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (Menorest)
Number of subjects: 325
Study: 9641566

Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SIT)
Number of subjects: 0
Study: 7653756

Group type: EXPERIMENTAL
Intervention: Somatostatin bolus 3.5 micrograms.kg‐1 intravenously plus an infusion of somatostatin 3.5 micrograms.kg‐1.h‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% as a placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Somatostatin and Control)
Number of subjects: 40
Study: 2671362

Group type: EXPERIMENTAL
Intervention: 2% butoconazole vaginal cream for three days
Number of subjects: 271

Group type: COMPARATOR
Intervention: 2% miconazole vaginal cream for seven days
Number of subjects: 271
Study: 791471

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil during postoperative follow-up
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1118
Study: 30995458

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking/jogging on a motor driven treadmill at approximately 70% of age-predicted maximum heart rate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (walking on the treadmill at 0.5 mph and 0% grade)
Number of subjects: 0
Study: 28592573

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exercise (interval training, 5 days a week, 30 min per session)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (lifestyle advice)
Number of subjects: 120
Study: 26089656

Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored self-management intervention
Number of subjects: 1325

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1325
Study: 22967275

Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 263
Study: 21906647

Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted quadrivalent influenza vaccine (QIV)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccines (TIV)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: MF59® adjuvant
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Different combinations of adjuvanted (ATIV) and non‐adjuvanted TIV and QIV
Number of subjects: 480
Study: 19193652

Group type: EXPERIMENTAL
Intervention: Lo-Pro GlideScope (LP-G)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flexible bronchoscope (FB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tongue pull
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Jaw thrust with tongue pull
Number of subjects: 28
Study: 16352680

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15172398

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 122
Study: 10794844

Group type: EXPERIMENTAL
Intervention: Baseline brain volumes of the anteromedial temporal lobe (hippocampus and parahippocampal gyrus) and global atrophy index
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline medial occipitotemporal and combined middle and inferior temporal gyri
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: APOE epsilon4 genotype
Number of subjects: 46
Study: 8780545

Group type: EXPERIMENTAL
Intervention: RT only
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: RT + A (RT + castration)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: RT only in patients < 70 years
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: RT + A in patients < 70 years
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Patients aged 70-74 years
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Patients older than 74 years
Number of subjects: 199
Study: 1961649

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (n = 44)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular treatment (n = 52)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Capillary loss
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Leakage
Number of subjects: 96
Study: 6119495

Group type: EXPERIMENTAL
Intervention: 1% glyceryl trinitrate ointment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (lanolin)
Number of subjects: 17
Study: 31596228

Group type: EXPERIMENTAL
Intervention: Salted mud
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: As is mud
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Over‐the‐Shelf mud
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated forearm
Number of subjects: 15
Study: 28651207

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both treatments (MCT and CBT)
Number of subjects: 90
Study: 26466081

Group type: EXPERIMENTAL
Intervention: Continuous time course trial
Number of subjects: 8
Study: 25086153

Group type: EXPERIMENTAL
Intervention: Blended Learning (BL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional Learning
Number of subjects: 81
Study: 20709514

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement/repair surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 50
Study: 20814331

Group type: EXPERIMENTAL
Intervention: Risperidone 1-mg single oral dose
Number of subjects: 71
Study: 18061060

Group type: EXPERIMENTAL
Intervention: Test vaccine (inactivated candidate vaccine for JEV)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Licensed vaccine (mouse‐brain‐derived vaccine)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Test vaccine
Number of subjects: 867

Group type: COMPARATOR
Intervention: Licensed vaccine
Number of subjects: 867
Study: 16283239

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15‐45 mg/day)
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Gliclazide (80‐320 mg/day)
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Metformin (850‐2,550 mg/day)
Number of subjects: 1269
Study: 12297475

Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (MMC) 2-4 mg, 4-6 mg, or 6-8 mg depending on tumor size
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen: 10 mg MMC, 40 mg PI, 300 mg CBP
Number of subjects: 36
Study: 10416522

Group type: EXPERIMENTAL
Intervention: Growth hormone for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 20
Study: 8789588

Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presyncopal symptoms
Number of subjects: 10
Study: 2917676

Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 7 days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 14 days
Number of subjects: 47
Study: 4393346

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 9
Study: 31432510

Group type: EXPERIMENTAL
Intervention: Balloon catheter (50-mL for 12 hours)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Oxytocin (low-dose infusion)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 204

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 204
Study: 30599916

Group type: EXPERIMENTAL
Intervention: Achillea millefolium 250 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Achillea millefolium 500 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29231586

Group type: EXPERIMENTAL
Intervention: Acupuncture (2-3 times per week, total of 14 treatments)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 44
Study: 25248340

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 34
Study: 23881337

Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 51
Study: 21199997

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring during usual sodium intake
Number of subjects: 46
Study: 19816812

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP) within a hypocaloric diet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Higher adherence to MDP during nutritional intervention
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Increase in Mediterranean diet score from baseline
Number of subjects: 41
Study: 21546491

Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset
Number of subjects: 434

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset (among thrombolyzed subjects)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Saline (control group, among thrombolyzed subjects)
Number of subjects: 434
Study: 16048138

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (10 g orally twice per day for 6 days, then 5 g daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 8
Study: 12351464

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo spray for 4 weeks
Number of subjects: 22
Study: 9840334

Group type: EXPERIMENTAL
Intervention: 24% oxygen enrichment during sleep
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ambient air during sleep
Number of subjects: 18
Study: 8010550

Group type: EXPERIMENTAL
Intervention: Parenteral magnesium sulfate (MgSO4)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined MgSO4-digoxin therapy
Number of subjects: 15
Study: 2470988

Group type: EXPERIMENTAL
Intervention: Cibenzoline 130 mg every 12 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cibenzoline 160 mg every 12 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinidine 300 mg every 6 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinidine 400 mg every 6 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 20
Study: 11763992

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide administered in the morning (05:00)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cisplatin and furosemide administered in the evening (17:00)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide (both morning and evening)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the evening (second course)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the first course (morning)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the second course (evening)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the second course (morning)
Number of subjects: 22
Study: 31621054

Group type: EXPERIMENTAL
Intervention: Vidofludimus
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 28440016

Group type: EXPERIMENTAL
Intervention: Short Transitional Intervention in Psychiatry (STeP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 29
Study: 27389036

Group type: EXPERIMENTAL
Intervention: Gated RT (respiratory monitoring)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Free-breathing RT
Number of subjects: 130
Study: 24885140

Group type: EXPERIMENTAL
Intervention: Video-assisted 4-stage approach (4-SA)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (instructor-led 4-SA)
Number of subjects: 256
Study: 21925823

Group type: EXPERIMENTAL
Intervention: VHS/DVD plus printed booklet
Number of subjects: 187

Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 187
Study: 20216060

Group type: EXPERIMENTAL
Intervention: Progressive resistance training on a bicycle ergometer and balance exercise (Training Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home‐based lower‐limb strengthening and balance exercise (Training Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 17266764

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily with initial dose of 200 mg for the first 2 weeks
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 3235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3235
Study: 15226138

Group type: EXPERIMENTAL
Intervention: Woman-focused intervention
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Revised National Institute on Drug Abuse standard intervention
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620